Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Revenue of Lyell Immunopharma, Inc. (LYEL)
Revenue in 2023 (TTM): $130 K
According to Lyell Immunopharma, Inc.'s latest financial reports the company's current revenue (TTM) is $130 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Lyell Immunopharma, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $130 K | $130 K | $-225,249,000 | $-234,632,000 | $-234,632,000 |
| 2022 | $84.68 M | $68.22 M | $-166,651,000 | $-183,118,000 | $-4,754,000 |
| 2021 | $10.65 M | $-3,885,000 | $-199,942,000 | $-250,219,000 | $-285,501,000 |
| 2020 | $7.76 M | $281 K | $-207,643,000 | $-204,472,000 | $-198,533,000 |
| 2019 | $657 K | $657 K | $-100,833,000 | $-129,377,000 | $-121,256,000 |